Literature DB >> 8562749

Spectrum and significance of bacteremia due to Moraxella catarrhalis.

J P Ioannidis1, M Worthington, J K Griffiths, D R Snydman.   

Abstract

Fifty-eight cases of bacteremia due to Moraxella catarrhalis, including seven that occurred in patients treated at our facilities, are analyzed. The host's medical history plays a major role in the presentation and outcome of M. catarrhalis bacteremia. Bacteremia is typically accompanied by pneumonia in adults with underlying respiratory disease. Many neutropenic patients do not manifest a focus of infection; in contrast, the source identified in healthy, immunocompetent patients is usually the upper airway or the ears. In the recent literature, it has been reported that a rash is typically absent in adults with bacteremic pneumonia and in immunocompetent hosts and that only some neutropenic patients have a rash. The prognosis is grave for patients with endocarditis and for patients with immunoglobulin deficiency or neutropenia not related to a hematologic malignancy. In addition, mortality is substantial among bacteremic patients with respiratory conditions or other chronic debilities, especially when respiratory copathogens are present. The prognosis is good for febrile neutropenic patients with underlying leukemia or lymphoma when the neutropenia resolves. When healthy, immunocompetent individuals are affected with M. catarrhalis bacteremia, their presentations range from self-limited febrile illness to life-threatening disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8562749     DOI: 10.1093/clinids/21.2.390

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

Review 1.  Lung infections. 2. Branhamella catarrhalis: epidemiological and clinical aspects of a human respiratory tract pathogen.

Authors:  T F Murphy
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

2.  Pulmonary thin-section CT findings in acute Moraxella catarrhalis pulmonary infection.

Authors:  F Okada; Y Ando; T Nakayama; S Tanoue; R Ishii; A Ono; M Watanabe; H Takaki; T Maeda; H Mori
Journal:  Br J Radiol       Date:  2010-12-01       Impact factor: 3.039

Review 3.  Moraxella catarrhalis: from emerging to established pathogen.

Authors:  Cees M Verduin; Cees Hol; André Fleer; Hans van Dijk; Alex van Belkum
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

4.  Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins.

Authors:  W G Hu; J Chen; J F Battey; X X Gu
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

5.  The transferrin binding protein B of Moraxella catarrhalis elicits bactericidal antibodies and is a potential vaccine antigen.

Authors:  L E Myers; Y P Yang; R P Du; Q Wang; R E Harkness; A B Schryvers; M H Klein; S M Loosmore
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

6.  Moraxella catarrhalis bacteraemia and prosthetic valve endocarditis.

Authors:  Lokesh Shahani; Shahriar Tavakoli Tabasi
Journal:  BMJ Case Rep       Date:  2015-10-23

Review 7.  Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.

Authors:  K McGregor; B J Chang; B J Mee; T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-04       Impact factor: 3.267

8.  Development of a disk diffusion method for testing Moraxella catarrhalis susceptibility using clinical and laboratory standards institute methods: a SENTRY antimicrobial surveillance program report.

Authors:  Jan M Bell; John D Turnidge; Ronald N Jones
Journal:  J Clin Microbiol       Date:  2009-05-20       Impact factor: 5.948

9.  Large unilateral pleural effusion secondary to Moraxella catarrhalis infection.

Authors:  Kushal Naha; Ravindra Prabhu
Journal:  Australas Med J       Date:  2011-09-30

10.  Cloning and expression of the Moraxella catarrhalis lactoferrin receptor genes.

Authors:  R P Du; Q Wang; Y P Yang; A B Schryvers; P Chong; M H Klein; S M Loosmore
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.